Q3 2024 Myriad Genetics Inc Earnings Call Transcript

Nov 7, 2024 / 09:30 PM GMT

Release Date Price: $17.95 (+1.13%)

Transcript 10-Q8-K

Key Points

Positve

Myriad Genetics Inc (MYGN) achieved 11% revenue growth in the third quarter compared to last year, reflecting both volume and revenue per test improvements across the portfolio.
The company generated approximately $150 million in gross profits and $14 million of adjusted EBITDA, with a positive adjusted EPS of $0.06.
Myriad Genetics Inc (MYGN) maintains a strong liquidity position with approximately $149 million in liquidity.
The company reported a 34% year-over-year increase in GeneSight revenues, with volume growth of 10% and improved revenue per test.
Myriad Genetics Inc (MYGN) continues to see positive momentum with its Precise Tumor test and has launched Foresight Universal Plus, potentially expanding market opportunities.

Negative

UnitedHealthcare updated its medical policy restricting access to multigene panel PGx testing, which could impact Myriad Genetics Inc (MYGN)'s GeneSight revenue.
GeneSight revenue associated with UnitedHealthcare's commercial business was approximately $40 million for the 12-month period ending third quarter of 2024, posing a potential risk if the policy change is implemented.
The hereditary cancer testing growth was partially impacted by slower growth of the BRACAnalysis CDx business in the US and internationally.
Typical seasonal softness in July and August affected volume growth in the third quarter.
The company faces ongoing challenges in reducing no-pay rates and improving payer coverage across its product portfolio.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MYGN.OQ - Myriad Genetics Inc
Q3 2024 Myriad Genetics Inc Earnings Call
Nov 07, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified Participant [1]
--------------------------------------------------------------------------------
Thanks. No. No in I see, good afternoon and welcome to the Myriad Genetics Third Quarter 2020 for financial earnings. I have friends and that will be the operator assisting in today. All lines have been placed on mute to prevent any background noise. After the speakers' remarks works, there will be a question and answer session. I would like to ask a question during this time, simply press star one on your telephone keypad. If you had to withdraw your question, press star one again, thank you and I would like to turn the call over to Matt Scalo. Please go ahead. Thank you, Frans, and good afternoon, and welcome to the Myriad Genetics Third Quarter 2024 earnings call. During the call, we will review financial results we released

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.